https://www.theguardian.com/cancer-revolutionaries/2022/jan/06/the-cancer-drug-that-turned-scientific-thinking-on-its-head-and-became-a-very-british-success-story

Olaparib is making an impact in the treatment of ovarian, breast, pancreatic and prostate cancers – and it’s a great example of how charities can support innovative but risky research when industry turns away. This is its journey from research to market

More than 40,000 people worldwide have been treated with the drug olaparib for ovarian, breast, pancreatic and prostate cancers. On its approval for use by drug regulators in 2014, it became the first of a new class of drugs called PARP inhibitors that kill cancer cells by undermining their ability to repair damage to their DNA.